Chronic Graft-versus-Host Disease-Implementation of the National Institutes of Health Consensus Criteria for Clinical Trials

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 4, 2008, Pages 379-384

  Griffith, Linda M ^a   Pavletic, Steven Z ^b   Lee, Stephanie J ^c   Martin, Paul J ^c   Schultz, Kirk R ^d   Vogelsang, Georgia B ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; GENETIC POLYMORPHISM; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH CARE FINANCING; HUMAN; MEDICAL RESEARCH; OUTCOMES RESEARCH; PROTEOMICS; RESOURCE MANAGEMENT; STAGING; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 40649105286     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.01.005     Document Type: Note

References (31)

1. A.H. Filipovich D. Weisdorf S. Pavletic National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 11 2005 945 956
2. H.M. Shulman D. Kleiner S.J. Lee Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report Biol Blood Marrow Transplant 12 2006 31 47
3. K.R. Schultz D.B. Miklos D. Fowler Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report Biol Blood Marrow Transplant 12 2006 126 137
4. S.Z. Pavletic P. Martin S.J. Lee Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report Biol Blood Marrow Transplant 12 2006 252 266
5. D. Couriel P.A. Carpenter C. Cutler Ancillary therapy and supportive care of chronic graft-versus-host-disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report Biol Blood Marrow Transplant 12 2006 375 396
6. P.J. Martin D. Weisdorf D. Przepiorka National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report Biol Blood Marrow Transplant 12 2006 491 505
7. M. Jagasia J. Giglia W. Chinratanalab Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria Biol Blood Marrow Transplant 13 2007 1207 1215
8. M. Arora S. Nagaraj J. Witte New classification of chronic graft versus host disease: added clarity from the consensus diagnoses Blood 110 2007 Abstract #41
9. D.A. Jacobsohn A.R. Chen M. Zahurak Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease J Clin Oncol 25 2007 4255 4261
10. S. Mitchell B. Reeve E. Cowen Feasibility and reproducibility of the new NIH consensus criteria to evaluate response in chronic GVHD—a pilot study Blood 106 2005 Abstract #3121
11. D. Wolff P.Y. Herzberg P. Heussner Prospective evaluation of the NIH staging criteria in chronic GVHD and correlation to quality of life—results of a German multicenter validation trial Blood 110 2007 Abstract #42
12. S. Yoshihara G. Yanik K.R. Cooke S. Mineishi Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 13 2007 749 759
13. M. Imanguli F. Hakim W. Swaim The balance of effector and regulatory cell populations in oral chronic GVHD: potential role of IL-15 Blood 110 2007 Abstract #1059
14. W.D. Shlomchik S.J. Lee D. Couriel S.Z. Pavletic Transplantation's greatest challenges: advances in chronic graft-versus-host disease Biol Blood Marrow Transplant 13 Suppl. 1 2007 2 10
15. Chu Y-W, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant . (accepted for publication).
16. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood . [E-pub ahead of schedule October 9, 2007, DOI 10.1182/blood-2007-08-106286 ].
17. K. She A.L. Gilman S. Aslanian Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease Biol Blood Marrow Transplant 13 2007 386 397
18. J.D. Dickinson I. Pusic C. Rader Soluble BAFF is elevated following allogeneic hematopoietic stem cell transplantation but is not an early predictor for the development of chronic GVHD Blood 110 2007 Abstract #167
19. S. Sarantopoulos K. Stevenson H.T. Kim High levels of B-cell activating factor in patients with active chronic graft-versus-host disease Clin Cancer Res 13 2007 6107 6114
20. A.M. Dickinson J.L. Harrold H. Cullup Haematopoietic stem cell transplantation: can our genes predict clinical outcome? Expert Rev Mol Med 9 2007 1 19
21. A.M. Dickinson Risk assessment in haematopoietic stem cell transplantation: pre-transplant patient and donor factors: non-HLA genetics Best Pract Res Clin Haematol 20 2007 189 207
22. E.M. Weissinger E. Schiffer B. Hertenstein Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood 109 2007 5511 5519
23. P.P. Wadia M.A. Coram A.J. Butte D.B. Miklos Allogeneic antibodies identify GVL targets CHAF1b and NuSAP1 in AML patients Blood 110 2007 Abstract #168
24. H.K. Al-Ali C. Nehring R. Krahl Donor CD34+ cell chimerism at day 28 and chronic graft-versus-host disease but not high-risk cytogenetics influence outcome of allogeneic hematopoietic cell transplantation following reduced intensity conditioning in patients with AML and MDS Blood 108 2006 Abstract #547
25. F. Baron M.B. Maris B.M. Sandmaier Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J Clin Oncol 23 2005 1993-2003
26. S.J. Lee J.P. Klein A.J. Barrett Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse Blood 100 2002 406 414
27. S. Baskar J.M. Levy M.R. Bishop C. Rader A human monoclonal antibody and antigen discovery platform based on allogeneic hematopoietic stem cell transplantation and phage display Keystone Symposia on Molecular and Cellular Biology; Antibodies as Drugs: From Basic Biology to the Clinic 2007 Abstract #213
28. R plus conventional therapy compared to conventional therapy alone in chronic GVHD Blood 108 2006 Abstract #758
29. C. Cutler D. Miklos H.T. Kim Rituximab for steroid-refractory chronic graft-versus-host disease Blood 108 2006 756 762
30. J.L.M. Ferrara C. Anasetti E. Stadtmauer Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007 Biol Blood Marrow Transplant 13 2007 1268 1285
31. C.J. Hackett D. Rotrosen H. Auchincloss A.S. Fauci Immunology research: challenges and opportunities in a time of budgetary constraint Nat Immunol 8 2007 114 117